psalexa

Embolotherapy Market Research Report: By Product (Embolic Agents, Support Devices), Procedure (Transcatheter Arterial Embolization, Transarterial Radioembolization/Selective Internal Radiation Therapy, Transarterial Chemoembolization), Indication (Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological and Nephrological Disorders, Gastrointestinal Disorders), End-User (Hospitals and Clinics, ASCs), Geographical Outlook (U.S., Canada, Germany, France, U.K., Italy, Spain, China, Japan, India, South Korea, Singapore, Brazil, Mexico, Saudi Arabia, South Africa) – Global Industry Analysis and Forecast to 2024

  • Published: September 2019
  • Report Code: LS11739
  • Available Format: PDF
  • Pages: 336

Chapter 1. Research Background

1.1 Research Objectives

1.2 Market Definition

1.3 Research Scope

1.3.1 Market Segmentation by Product

1.3.2 Market Segmentation by Procedure

1.3.3 Market Segmentation by Indication

1.3.4 Market Segmentation by End User

1.3.5 Market Segmentation by Region

1.3.6 Analysis Period

1.3.7 Market Data Reporting Unit

1.3.7.1 Value

1.3.7.2 Volume

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Split of Primary Research Information

2.2.2 Breakdown of Primary Research by Industry Participant

2.2.3 Breakdown of Primary Research by Company Type

2.2.4 Breakdown of Primary Research by Company and Designation

2.3 Baseline-Methodology

2.4 Market Size Estimation

2.5 KOLs’ Sources

2.6 Data Triangulation

2.7 Assumptions for the Study

Chapter 3. Executive Summary

3.1 Voice of KOLS

Chapter 4. Introduction

4.1 Definition of Market Segments

4.1.1 By Product

4.1.1.1 Embolic agents

4.1.1.1.1 Microspheres

4.1.1.1.2 Embolic coils

4.1.1.1.3 Liquid embolic agents

4.1.1.1.4 Embolic plug systems

4.1.1.1.5 Detachable balloons

4.1.1.2 Support devices

4.1.1.2.1 Microcatheters

4.1.1.2.2 Guidewires

4.1.2 By Procedure

4.1.2.1 TAE

4.1.2.2 TARE/SIRT

4.1.2.3 TACE

4.1.3 By Indication

4.1.3.1 Cancer

4.1.3.1.1 Kidney

4.1.3.1.2 Liver

4.1.3.1.3 Others

4.1.3.2 Peripheral vascular diseases

4.1.3.3 Neurological diseases

4.1.3.3.1 Cerebral aneurysm

4.1.3.3.2 Arteriovenous malformation and fistulas

4.1.3.4 Urological and nephrological disorders

4.1.3.5 Gastrointestinal disorders

4.1.4 By End User

4.1.4.1 Hospitals and clinics

4.1.4.2 ASCs

4.1.4.3 Others

4.2 Market Dynamics

4.2.1 Trends

4.2.1.1 Increase in the number of product approvals and launches

4.2.1.2 Increasing number of acquisitions

4.2.2 Drivers

4.2.2.1 Growing patient pool for embolotherapy

4.2.2.2 Increasing prevalence of chronic and lifestyle-associated diseases

4.2.2.3 Growing medical tourism

4.2.2.4 Rising healthcare expenditure and improving healthcare infrastructure

4.2.2.5 Growing preference for MISs

4.2.2.6 Impact analysis of drivers on market forecast

4.2.3 Restraints

4.2.3.1 Risks and challenges associated with embolization

4.2.3.2 Product recalls

4.2.3.3 Dearth of skilled radiologists

4.2.3.4 Impact analysis of restraints on market forecast

4.2.4 Opportunities

4.2.4.1 Growing applications of embolic agents

4.2.4.2 Untapped market in developing economies

4.3 Porter’s Five Forces Analysis

4.4 Regulatory Framework Analysis

4.4.1 U.S.

4.4.2 Europe

4.4.3 APAC

4.4.4 LATAM

4.4.5 MEA

Chapter 5. Embolotherapy Procedures in 7MM

5.1 7MM

5.2 U.S.

5.3 U.K.

5.4 Germany

5.5 France

5.6 Italy

5.7 Spain

5.8 Japan

Chapter 6. Global Market Size and Forecast

6.1 Global Market Size and Forecast

6.2 By Product

6.2.1 Embolic Agents Market, by Type

6.2.2 Embolotherapy Support Devices Market, by Type

6.3 By Procedure

6.4 By Indication

6.4.1 Embolotherapy Market for Cancer, by Type

6.4.2 Embolotherapy Market for Neurological Diseases, by Type

6.5 By End User

6.6 By Region

Chapter 7. North America Market Size and Forecast

7.1 By Product

7.1.1 Embolic Agents Market, by Type

7.1.2 Embolotherapy Support Devices Market, by Type

7.2 By Procedure

7.3 By Indication

7.3.1 Embolotherapy Market for Cancer, by Type

7.3.2 Embolotherapy Market for Neurological Diseases, by Type

7.4 By End User

7.5 By Country

7.5.1 U.S. Market Size and Forecast

7.5.1.1 By product

7.5.1.1.1 Embolic agents market, by type

7.5.1.1.2 Embolotherapy support devices market, by type

7.5.1.2 By procedure

7.5.1.3 By indication

7.5.1.3.1 Embolotherapy market for cancer, by type

7.5.1.3.2 Embolotherapy market for neurological diseases, by type

7.5.1.4 By end user

7.5.2 Canada Market Size and Forecast

7.5.2.1 By product

7.5.2.1.1 Embolic agents market, by type

7.5.2.1.2 Embolotherapy support devices market, by type

7.5.2.2 By procedure

7.5.2.3 By indication

7.5.2.3.1 Embolotherapy market for cancer, by type

7.5.2.3.2 Embolotherapy market for neurological diseases, by type

7.5.2.4 By end user

Chapter 8. Europe Market Size and Forecast

8.1 By Product

8.1.1 Embolic Agents Market, by Type

8.1.2 Embolotherapy Support Devices Market, by Type

8.2 By Procedure

8.3 By Indication

8.3.1 Embolotherapy Market for Cancer, by Type

8.3.2 Embolotherapy Market for Neurological Diseases, by Type

8.4 By End User

8.5 By Country

8.5.1 Germany Market Size and Forecast

8.5.1.1 By product

8.5.1.1.1 Embolic agents market, by type

8.5.1.1.2 Embolotherapy support devices market, by type

8.5.1.2 By procedure

8.5.1.3 By indication

8.5.1.3.1 Embolotherapy market for cancer, by type

8.5.1.3.2 Embolotherapy market for neurological diseases, by type

8.5.1.4 By end user

8.5.2 France Market Size and Forecast

8.5.2.1 By product

8.5.2.1.1 Embolic agents market, by type

8.5.2.1.2 Embolotherapy support devices market, by type

8.5.2.2 By procedure

8.5.2.3 By indication

8.5.2.3.1 Embolotherapy market for cancer, by type

8.5.2.3.2 Embolotherapy market for neurological diseases, by type

8.5.2.4 By end user

8.5.3 U.K. Market Size and Forecast

8.5.3.1 By product

8.5.3.1.1 Embolic agents market, by type

8.5.3.1.2 Embolotherapy support devices market, by type

8.5.3.2 By procedure

8.5.3.3 By indication

8.5.3.3.1 Embolotherapy market for cancer, by type

8.5.3.3.2 Embolotherapy market for neurological diseases, by type

8.5.3.4 By end user

8.5.4 Italy Market Size and Forecast

8.5.4.1 By product

8.5.4.1.1 Embolic agents market, by type

8.5.4.1.2 Embolotherapy support devices market, by type

8.5.4.2 By procedure

8.5.4.3 By indication

8.5.4.3.1 Embolotherapy market for cancer, by type

8.5.4.3.2 Embolotherapy market for neurological diseases, by type

8.5.4.4 By end user

8.5.5 Spain Market Size and Forecast

8.5.5.1 By product

8.5.5.1.1 Embolic agents market, by type

8.5.5.1.2 Embolotherapy support devices market, by type

8.5.5.2 By procedure

8.5.5.3 By indication

8.5.5.3.1 Embolotherapy market for cancer, by type

8.5.5.3.2 Embolotherapy market for neurological diseases, by type

8.5.5.4 By end user

Chapter 9. APAC Market Size and Forecast

9.1 By Product

9.1.1 Embolic Agents Market, by Type

9.1.2 Embolotherapy Support Devices Market, by Type

9.2 By Procedure

9.3 By Indication

9.3.1 Embolotherapy Market for Cancer, by Type

9.3.2 Embolotherapy Market for Neurological Diseases, by Type

9.4 By End User

9.5 By Country

9.5.1 China Market Size and Forecast

9.5.1.1 By product

9.5.1.1.1 Embolic agents market, by type

9.5.1.1.2 Embolotherapy support devices market, by type

9.5.1.2 By procedure

9.5.1.3 By indication

9.5.1.3.1 Embolotherapy market for cancer, by type

9.5.1.3.2 Embolotherapy market for neurological diseases, by type

9.5.1.4 By end user

9.5.2 Japan Market Size and Forecast

9.5.2.1 By product

9.5.2.1.1 Embolic agents market, by type

9.5.2.1.2 Embolotherapy support devices market, by type

9.5.2.2 By procedure

9.5.2.3 By indication

9.5.2.3.1 Embolotherapy market for cancer, by type

9.5.2.3.2 Embolotherapy market for neurological diseases, by type

9.5.2.4 By end user

9.5.3 India Market Size and Forecast

9.5.3.1 By product

9.5.3.1.1 Embolic agents market, by type

9.5.3.1.2 Embolotherapy support devices market, by type

9.5.3.2 By procedure

9.5.3.3 By indication

9.5.3.3.1 Embolotherapy market for cancer, by type

9.5.3.3.2 Embolotherapy market for neurological diseases, by type

9.5.3.4 By end user

9.5.4 South Korea Market Size and Forecast

9.5.4.1 By product

9.5.4.1.1 Embolic agents market, by type

9.5.4.1.2 Embolotherapy support devices market, by type

9.5.4.2 By procedure

9.5.4.3 By indication

9.5.4.3.1 Embolotherapy market for cancer, by type

9.5.4.3.2 Embolotherapy market for neurological diseases, by type

9.5.4.4 By end user

9.5.5 Singapore Market Size and Forecast

9.5.5.1 By product

9.5.5.1.1 Embolic agents market, by type

9.5.5.1.2 Embolotherapy support devices market, by type

9.5.5.2 By procedure

9.5.5.3 By indication

9.5.5.3.1 Embolotherapy market for cancer, by type

9.5.5.3.2 Embolotherapy market for neurological diseases, by type

9.5.5.4 By end user

Chapter 10. LATAM Market Size and Forecast

10.1 By Product

10.1.1 Embolic Agents Market, by Type

10.1.2 Embolotherapy Support Devices Market, by Type

10.2 By Procedure

10.3 By Indication

10.3.1 Embolotherapy Market for Cancer, by Type

10.3.2 Embolotherapy Market for Neurological Diseases, by Type

10.4 By End User

10.5 By Country

10.5.1 Brazil Market Size and Forecast

10.5.1.1 By product

10.5.1.1.1 Embolic agents market, by type

10.5.1.1.2 Embolotherapy support devices market, by type

10.5.1.2 By procedure

10.5.1.3 By indication

10.5.1.3.1 Embolotherapy market for cancer, by type

10.5.1.3.2 Embolotherapy market for neurological diseases, by type

10.5.1.4 By end user

10.5.2 Mexico Market Size and Forecast

10.5.2.1 By product

10.5.2.1.1 Embolic agents market, by type

10.5.2.1.2 Embolotherapy support devices market, by type

10.5.2.2 By procedure

10.5.2.3 By indication

10.5.2.3.1 Embolotherapy market for cancer, by type

10.5.2.3.2 Embolotherapy market for neurological diseases, by type

10.5.2.4 By end user

Chapter 11. MEA Market Size and Forecast

11.1 By Product

11.1.1 Embolic Agents Market, by Type

11.1.2 Embolotherapy Support Devices Market, by Type

11.2 By Procedure

11.3 By Indication

11.3.1 Embolotherapy Market for Cancer, by Type

11.3.2 Embolotherapy Market for Neurological Diseases, by Type

11.4 By End User

11.5 By Country

11.5.1 Saudi Arabia Market Size and Forecast

11.5.1.1 By product

11.5.1.1.1 Embolic agents market, by type

11.5.1.1.2 Embolotherapy support devices market, by type

11.5.1.2 By procedure

11.5.1.3 By indication

11.5.1.3.1 Embolotherapy market for cancer, by type

11.5.1.3.2 Embolotherapy market for neurological diseases, by type

11.5.1.4 By end user

11.5.2 South Africa Market Size and Forecast

11.5.2.1 By product

11.5.2.1.1 Embolic agents market, by type

11.5.2.1.2 Embolotherapy support devices market, by type

11.5.2.2 By procedure

11.5.2.3 By indication

11.5.2.3.1 Embolotherapy market for cancer, by type

11.5.2.3.2 Embolotherapy market for neurological diseases, by type

11.5.2.4 By end user

Chapter 12. Competitive Landscape

12.1 List of Other Players

12.2 Strategic Developments of Key Players

12.2.1 Product Launches & Approvals

12.2.2 Collaborations

12.2.3 Acquisitions

12.2.4 Expansions

Chapter 13. Company Profiles

13.1 Stryker Corporation

13.1.1 Business Overview

13.1.2 Product and Service Offerings

13.1.3 Key Financial Summary

13.2 Sirtex Medical Limited

13.2.1 Business Overview

13.2.2 Product and Service Offerings

13.2.3 Key Financial Summary

13.3 Merit Medical Systems Inc.

13.3.1 Business Overview

13.3.2 Product and Service Offerings

13.3.3 Key Financial Summary

13.4 Meril Life Sciences Pvt. Ltd.

13.4.1 Business Overview

13.4.2 Product and Service Offerings

13.5 Acandis GmbH

13.5.1 Business Overview

13.5.2 Product and Service Offerings

13.6 Terumo Corporation

13.6.1 Business Overview

13.6.2 Product and Service Offerings

13.6.3 Key Financial Summary

13.7 Medtronic plc

13.7.1 Business Overview

13.7.2 Product and Service Offerings

13.7.3 Key Financial Summary

13.8 Kaneka Corporation

13.8.1 Business Overview

13.8.2 Product and Service Offerings

13.8.3 Key Financial Summary

13.9 Johnson & Johnson

13.9.1 Business Overview

13.9.2 Product and Service Offerings

13.9.3 Key Financial Summary

13.10 Boston Scientific Corporation

13.10.1 Business Overview

13.10.2 Product and Service Offerings

13.10.3 Key Financial Summary

13.11 Abbott Laboratories

13.11.1 Business Overview

13.11.2 Product and Service Offerings

13.11.3 Key Financial Summary

13.12 Guerbet

13.12.1 Business Overview

13.12.2 Product and Service Offerings

13.12.3 Key Financial Summary

13.13 BALT EXTRUSION SAS

13.13.1 Business Overview

13.13.2 Product and Service Offerings

Chapter 14. Appendix

14.1 Abbreviations

14.2 Sources and References

14.3 Related Reports

 

LIST OF TABLES

 

TABLE 1 ANALYSIS PERIOD OF THE STUDY

TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 REGULATORY AND APPROVAL BODIES FOR MEDICAL DEVICES IN LATAM COUNTRIES

TABLE 5 NUMBER OF EMBOLOTHERAPY PROCEDURES IN 7MM (2014–2018)

TABLE 6 NUMBER OF EMBOLOTHERAPY PROCEDURES IN 7MM (2019–2024)

TABLE 7 NUMBER OF EMBOLOTHERAPY PROCEDURES IN THE U.S. (2014–2018)

TABLE 8 NUMBER OF EMBOLOTHERAPY PROCEDURES IN THE U.S. (2019–2024)

TABLE 9 NUMBER OF EMBOLOTHERAPY PROCEDURES IN THE U.K. (2014–2018)

TABLE 10 NUMBER OF EMBOLOTHERAPY PROCEDURES IN THE U.K. (2019–2024)

TABLE 11 NUMBER OF EMBOLOTHERAPY PROCEDURES IN GERMANY (2014–2018)

TABLE 12 NUMBER OF EMBOLOTHERAPY PROCEDURES IN GERMANY (2019–2024)

TABLE 13 NUMBER OF EMBOLOTHERAPY PROCEDURES IN FRANCE (2014–2018)

TABLE 14 NUMBER OF EMBOLOTHERAPY PROCEDURES IN FRANCE (2019–2024)

TABLE 15 NUMBER OF EMBOLOTHERAPY PROCEDURES IN ITALY (2014–2018)

TABLE 16 NUMBER OF EMBOLOTHERAPY PROCEDURES IN ITALY (2019–2024)

TABLE 17 NUMBER OF EMBOLOTHERAPY PROCEDURES IN SPAIN (2014–2018)

TABLE 18 NUMBER OF EMBOLOTHERAPY PROCEDURES IN SPAIN (2019–2024)

TABLE 19 NUMBER OF EMBOLOTHERAPY PROCEDURES IN JAPAN (2014–2018)

TABLE 20 NUMBER OF EMBOLOTHERAPY PROCEDURES IN JAPAN (2019–2024)

TABLE 21 GLOBAL EMBOLOTHERAPY MARKET, BY PRODUCT, UNIT (2014–2018)

TABLE 22 GLOBAL EMBOLOTHERAPY MARKET, BY PRODUCT, UNIT (2019–2024)

TABLE 23 GLOBAL EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2018)

TABLE 24 GLOBAL EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)

TABLE 25 GLOBAL EMBOLIC AGENTS MARKET, BY TYPE, UNIT (2014–2018)

TABLE 26 GLOBAL EMBOLIC AGENTS MARKET, BY TYPE, UNIT (2019–2024)

TABLE 27 GLOBAL EMBOLIC AGENTS MARKET, BY TYPE, $M (2014–2018)

TABLE 28 GLOBAL EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)

TABLE 29 GLOBAL EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, UNIT (2014–2018)

TABLE 30 GLOBAL EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, UNIT (2019–2024)

TABLE 31 GLOBAL EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2014–2018)

TABLE 32 GLOBAL EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 33 GLOBAL EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2018)

TABLE 34 GLOBAL EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)

TABLE 35 GLOBAL EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2018)

TABLE 36 GLOBAL EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)

TABLE 37 GLOBAL EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2014–2018)

TABLE 38 GLOBAL EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)

TABLE 39 GLOBAL EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2014–2018)

TABLE 40 GLOBAL EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)

TABLE 41 GLOBAL EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2018)

TABLE 42 GLOBAL EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)

TABLE 43 GLOBAL EMBOLOTHERAPY MARKET, BY REGION, $M (2014–2018)

TABLE 44 GLOBAL EMBOLOTHERAPY MARKET, BY REGION, $M (2019–2024)

TABLE 45 NORTH AMERICA EMBOLOTHERAPY MARKET, BY PRODUCT, UNIT (2014–2018)

TABLE 46 NORTH AMERICA EMBOLOTHERAPY MARKET, BY PRODUCT, UNIT (2019–2024)

TABLE 47 NORTH AMERICA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2018)

TABLE 48 NORTH AMERICA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)

TABLE 49 NORTH AMERICA EMBOLIC AGENTS MARKET, BY TYPE, UNIT (2014–2018)

TABLE 50 NORTH AMERICA EMBOLIC AGENTS MARKET, BY TYPE, UNIT (2019–2024)

TABLE 51 NORTH AMERICA EMBOLIC AGENTS MARKET, BY TYPE, $M (2014–2018)

TABLE 52 NORTH AMERICA EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)

TABLE 53 NORTH AMERICA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, UNIT (2014–2018)

TABLE 54 NORTH AMERICA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, UNIT (2019–2024)

TABLE 55 NORTH AMERICA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2014–2018)

TABLE 56 NORTH AMERICA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 57 NORTH AMERICA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2018)

TABLE 58 NORTH AMERICA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)

TABLE 59 NORTH AMERICA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2018)

TABLE 60 NORTH AMERICA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)

TABLE 61 NORTH AMERICA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2014–2018)

TABLE 62 NORTH AMERICA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)

TABLE 63 NORTH AMERICA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2014–2018)

TABLE 64 NORTH AMERICA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)

TABLE 65 NORTH AMERICA EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2018)

TABLE 66 NORTH AMERICA EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)

TABLE 67 NORTH AMERICA EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2014–2018)

TABLE 68 NORTH AMERICA EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2019–2024)

TABLE 69 U.S. EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2018)

TABLE 70 U.S. EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)

TABLE 71 U.S. EMBOLIC AGENTS MARKET, BY TYPE, $M (2014–2018)

TABLE 72 U.S. EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)

TABLE 73 U.S. EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2014–2018)

TABLE 74 U.S. EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 75 U.S. EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2018)

TABLE 76 U.S. EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)

TABLE 77 U.S. EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2018)

TABLE 78 U.S. EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)

TABLE 79 U.S. EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2014–2018)

TABLE 80 U.S. EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)

TABLE 81 U.S. EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2014–2018)

TABLE 82 U.S. EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)

TABLE 83 U.S. EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2018)

TABLE 84 U.S. EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)

TABLE 85 CANADA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2018)

TABLE 86 CANADA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)

TABLE 87 CANADA EMBOLIC AGENTS MARKET, BY TYPE, $M (2014–2018)

TABLE 88 CANADA EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)

TABLE 89 CANADA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2014–2018)

TABLE 90 CANADA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 91 CANADA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2018)

TABLE 92 CANADA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)

TABLE 93 CANADA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2018)

TABLE 94 CANADA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)

TABLE 95 CANADA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2014–2018)

TABLE 96 CANADA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)

TABLE 97 CANADA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2014–2018)

TABLE 98 CANADA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)

TABLE 99 CANADA EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2018)

TABLE 100 CANADA EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)

TABLE 101 EUROPE EMBOLOTHERAPY MARKET, BY PRODUCT, UNIT (2014–2018)

TABLE 102 EUROPE EMBOLOTHERAPY MARKET, BY PRODUCT, UNIT (2019–2024)

TABLE 103 EUROPE EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2018)

TABLE 104 EUROPE EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)

TABLE 105 EUROPE EMBOLIC AGENTS MARKET, BY TYPE, UNIT (2014–2018)

TABLE 106 EUROPE EMBOLIC AGENTS MARKET, BY TYPE, UNIT (2019–2024)

TABLE 107 EUROPE EMBOLIC AGENTS MARKET, BY TYPE, $M (2014–2018)

TABLE 108 EUROPE EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)

TABLE 109 EUROPE EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, UNIT (2014–2018)

TABLE 110 EUROPE EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, UNIT (2019–2024)

TABLE 111 EUROPE EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2014–2018)

TABLE 112 EUROPE EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 113 EUROPE EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2018)

TABLE 114 EUROPE EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)

TABLE 115 EUROPE EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2018)

TABLE 116 EUROPE EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)

TABLE 117 EUROPE EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2014–2018)

TABLE 118 EUROPE EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)

TABLE 119 EUROPE EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2014–2018)

TABLE 120 EUROPE EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)

TABLE 121 EUROPE EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2018)

TABLE 122 EUROPE EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)

TABLE 123 EUROPE EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2014–2018)

TABLE 124 EUROPE EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2019–2024)

TABLE 125 GERMANY EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2018)

TABLE 126 GERMANY EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)

TABLE 127 GERMANY EMBOLIC AGENTS MARKET, BY TYPE, $M (2014–2018)

TABLE 128 GERMANY EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)

TABLE 129 GERMANY EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2014–2018)

TABLE 130 GERMANY EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 131 GERMANY EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2018)

TABLE 132 GERMANY EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)

TABLE 133 GERMANY EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2018)

TABLE 134 GERMANY EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)

TABLE 135 GERMANY EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2014–2018)

TABLE 136 GERMANY EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)

TABLE 137 GERMANY EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2014–2018)

TABLE 138 GERMANY EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)

TABLE 139 GERMANY EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2018)

TABLE 140 GERMANY EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)

TABLE 141 FRANCE EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2018)

TABLE 142 FRANCE EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)

TABLE 143 FRANCE EMBOLIC AGENTS MARKET, BY TYPE, $M (2014–2018)

TABLE 144 FRANCE EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)

TABLE 145 FRANCE EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2014–2018)

TABLE 146 FRANCE EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 147 FRANCE EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2018)

TABLE 148 FRANCE EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)

TABLE 149 FRANCE EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2018)

TABLE 150 FRANCE EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)

TABLE 151 FRANCE EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2014–2018)

TABLE 152 FRANCE EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)

TABLE 153 FRANCE EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2014–2018)

TABLE 154 FRANCE EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)

TABLE 155 FRANCE EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2018)

TABLE 156 FRANCE EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)

TABLE 157 U.K. EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2018)

TABLE 158 U.K. EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)

TABLE 159 U.K. EMBOLIC AGENTS MARKET, BY TYPE, $M (2014–2018)

TABLE 160 U.K. EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)

TABLE 161 U.K. EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2014–2018)

TABLE 162 U.K. EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 163 U.K. EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2018)

TABLE 164 U.K. EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)

TABLE 165 U.K. EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2018)

TABLE 166 U.K. EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)

TABLE 167 U.K. EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2014–2018)

TABLE 168 U.K. EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)

TABLE 169 U.K. EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2014–2018)

TABLE 170 U.K. EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)

TABLE 171 U.K. EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2018)

TABLE 172 U.K. EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)

TABLE 173 ITALY EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2018)

TABLE 174 ITALY EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)

TABLE 175 ITALY EMBOLIC AGENTS MARKET, BY TYPE, $M (2014–2018)

TABLE 176 ITALY EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)

TABLE 177 ITALY EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2014–2018)

TABLE 178 ITALY EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 179 ITALY EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2018)

TABLE 180 ITALY EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)

TABLE 181 ITALY EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2018)

TABLE 182 ITALY EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)

TABLE 183 ITALY EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2014–2018)

TABLE 184 ITALY EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)

TABLE 185 ITALY EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2014–2018)

TABLE 186 ITALY EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)

TABLE 187 ITALY EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2018)

TABLE 188 ITALY EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)

TABLE 189 SPAIN EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2018)

TABLE 190 SPAIN EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)

TABLE 191 SPAIN EMBOLIC AGENTS MARKET, BY TYPE, $M (2014–2018)

TABLE 192 SPAIN EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)

TABLE 193 SPAIN EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2014–2018)

TABLE 194 SPAIN EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 195 SPAIN EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2018)

TABLE 196 SPAIN EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)

TABLE 197 SPAIN EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2018)

TABLE 198 SPAIN EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)

TABLE 199 SPAIN EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2014–2018)

TABLE 200 SPAIN EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)

TABLE 201 SPAIN EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2014–2018)

TABLE 202 SPAIN EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)

TABLE 203 SPAIN EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2018)

TABLE 204 SPAIN EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)

TABLE 205 APAC EMBOLOTHERAPY MARKET, BY PRODUCT, UNIT (2014–2018)

TABLE 206 APAC EMBOLOTHERAPY MARKET, BY PRODUCT, UNIT (2019–2024)

TABLE 207 APAC EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2018)

TABLE 208 APAC EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)

TABLE 209 APAC EMBOLIC AGENTS MARKET, BY TYPE, UNIT (2014–2018)

TABLE 210 APAC EMBOLIC AGENTS MARKET, BY TYPE, UNIT (2019–2024)

TABLE 211 APAC EMBOLIC AGENTS MARKET, BY TYPE, $M (2014–2018)

TABLE 212 APAC EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)

TABLE 213 APAC EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, UNIT (2014–2018)

TABLE 214 APAC EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, UNIT (2019–2024)

TABLE 215 APAC EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2014–2018)

TABLE 216 APAC EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 217 APAC EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2018)

TABLE 218 APAC EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)

TABLE 219 APAC EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2018)

TABLE 220 APAC EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)

TABLE 221 APAC EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2014–2018)

TABLE 222 APAC EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)

TABLE 223 APAC EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2014–2018)

TABLE 224 APAC EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)

TABLE 225 APAC EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2018)

TABLE 226 APAC EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)

TABLE 227 APAC EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2014–2018)

TABLE 228 APAC EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2019–2024)

TABLE 229 CHINA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2018)

TABLE 230 CHINA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)

TABLE 231 CHINA EMBOLIC AGENTS MARKET, BY TYPE, $M (2014–2018)

TABLE 232 CHINA EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)

TABLE 233 CHINA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2014–2018)

TABLE 234 CHINA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 235 CHINA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2018)

TABLE 236 CHINA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)

TABLE 237 CHINA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2018)

TABLE 238 CHINA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)

TABLE 239 CHINA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2014–2018)

TABLE 240 CHINA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)

TABLE 241 CHINA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2014–2018)

TABLE 242 CHINA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)

TABLE 243 CHINA EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2018)

TABLE 244 CHINA EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)

TABLE 245 JAPAN EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2018)

TABLE 246 JAPAN EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)

TABLE 247 JAPAN EMBOLIC AGENTS MARKET, BY TYPE, $M (2014–2018)

TABLE 248 JAPAN EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)

TABLE 249 JAPAN EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2014–2018)

TABLE 250 JAPAN EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 251 JAPAN EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2018)

TABLE 252 JAPAN EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)

TABLE 253 JAPAN EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2018)

TABLE 254 JAPAN EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)

TABLE 255 JAPAN EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2014–2018)

TABLE 256 JAPAN EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)

TABLE 257 JAPAN EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2014–2018)

TABLE 258 JAPAN EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)

TABLE 259 JAPAN EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2018)

TABLE 260 JAPAN EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)

TABLE 261 INDIA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2018)

TABLE 262 INDIA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)

TABLE 263 INDIA EMBOLIC AGENTS MARKET, BY TYPE, $M (2014–2018)

TABLE 264 INDIA EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)

TABLE 265 INDIA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2014–2018)

TABLE 266 INDIA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 267 INDIA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2018)

TABLE 268 INDIA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)

TABLE 269 INDIA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2018)

TABLE 270 INDIA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)

TABLE 271 INDIA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2014–2018)

TABLE 272 INDIA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)

TABLE 273 INDIA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2014–2018)

TABLE 274 INDIA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)

TABLE 275 INDIA EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2018)

TABLE 276 INDIA EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)

TABLE 277 SOUTH KOREA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2018)

TABLE 278 SOUTH KOREA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)

TABLE 279 SOUTH KOREA EMBOLIC AGENTS MARKET, BY TYPE, $M (2014–2018)

TABLE 280 SOUTH KOREA EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)

TABLE 281 SOUTH KOREA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2014–2018)

TABLE 282 SOUTH KOREA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 283 SOUTH KOREA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2018)

TABLE 284 SOUTH KOREA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)

TABLE 285 SOUTH KOREA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2018)

TABLE 286 SOUTH KOREA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)

TABLE 287 SOUTH KOREA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2014–2018)

TABLE 288 SOUTH KOREA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)

TABLE 289 SOUTH KOREA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2014–2018)

TABLE 290 SOUTH KOREA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)

TABLE 291 SOUTH KOREA EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2018)

TABLE 292 SOUTH KOREA EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)

TABLE 293 SINGAPORE EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2018)

TABLE 294 SINGAPORE EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)

TABLE 295 SINGAPORE EMBOLIC AGENTS MARKET, BY TYPE, $M (2014–2018)

TABLE 296 SINGAPORE EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)

TABLE 297 SINGAPORE EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2014–2018)

TABLE 298 SINGAPORE EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 299 SINGAPORE EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2018)

TABLE 300 SINGAPORE EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)

TABLE 301 SINGAPORE EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2018)

TABLE 302 SINGAPORE EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)

TABLE 303 SINGAPORE EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2014–2018)

TABLE 304 SINGAPORE EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)

TABLE 305 SINGAPORE EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2014–2018)

TABLE 306 SINGAPORE EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)

TABLE 307 SINGAPORE EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2018)

TABLE 308 SINGAPORE EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)

TABLE 309 LATAM EMBOLOTHERAPY MARKET, BY PRODUCT, UNIT (2014–2018)

TABLE 310 LATAM EMBOLOTHERAPY MARKET, BY PRODUCT, UNIT (2019–2024)

TABLE 311 LATAM EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2018)

TABLE 312 LATAM EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)

TABLE 313 LATAM EMBOLIC AGENTS MARKET, BY TYPE, UNIT (2014–2018)

TABLE 314 LATAM EMBOLIC AGENTS MARKET, BY TYPE, UNIT (2019–2024)

TABLE 315 LATAM EMBOLIC AGENTS MARKET, BY TYPE, $M (2014–2018)

TABLE 316 LATAM EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)

TABLE 317 LATAM EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, UNIT (2014–2018)

TABLE 318 LATAM EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, UNIT (2019–2024)

TABLE 319 LATAM EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2014–2018)

TABLE 320 LATAM EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 321 LATAM EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2018)

TABLE 322 LATAM EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)

TABLE 323 LATAM EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2018)

TABLE 324 LATAM EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)

TABLE 325 LATAM EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2014–2018)

TABLE 326 LATAM EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)

TABLE 327 LATAM EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2014–2018)

TABLE 328 LATAM EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)

TABLE 329 LATAM EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2018)

TABLE 330 LATAM EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)

TABLE 331 LATAM EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2014–2018)

TABLE 332 LATAM EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2019–2024)

TABLE 333 BRAZIL EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2018)

TABLE 334 BRAZIL EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)

TABLE 335 BRAZIL EMBOLIC AGENTS MARKET, BY TYPE, $M (2014–2018)

TABLE 336 BRAZIL EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)

TABLE 337 BRAZIL EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2014–2018)

TABLE 338 BRAZIL EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 339 BRAZIL EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2018)

TABLE 340 BRAZIL EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)

TABLE 341 BRAZIL EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2018)

TABLE 342 BRAZIL EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)

TABLE 343 BRAZIL EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2014–2018)

TABLE 344 BRAZIL EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)

TABLE 345 BRAZIL EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2014–2018)

TABLE 346 BRAZIL EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)

TABLE 347 BRAZIL EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2018)

TABLE 348 BRAZIL EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)

TABLE 349 MEXICO EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2018)

TABLE 350 MEXICO EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)

TABLE 351 MEXICO EMBOLIC AGENTS MARKET, BY TYPE, $M (2014–2018)

TABLE 352 MEXICO EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)

TABLE 353 MEXICO EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2014–2018)

TABLE 354 MEXICO EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 355 MEXICO EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2018)

TABLE 356 MEXICO EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)

TABLE 357 MEXICO EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2018)

TABLE 358 MEXICO EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)

TABLE 359 MEXICO EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2014–2018)

TABLE 360 MEXICO EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)

TABLE 361 MEXICO EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2014–2018)

TABLE 362 MEXICO EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)

TABLE 363 MEXICO EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2018)

TABLE 364 MEXICO EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)

TABLE 365 MEA EMBOLOTHERAPY MARKET, BY PRODUCT, UNIT (2014–2018)

TABLE 366 MEA EMBOLOTHERAPY MARKET, BY PRODUCT, UNIT (2019–2024)

TABLE 367 MEA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2018)

TABLE 368 MEA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)

TABLE 369 MEA EMBOLIC AGENTS MARKET, BY TYPE, UNIT (2014–2018)

TABLE 370 MEA EMBOLIC AGENTS MARKET, BY TYPE, UNIT (2019–2024)

TABLE 371 MEA EMBOLIC AGENTS MARKET, BY TYPE, $M (2014–2018)

TABLE 372 MEA EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)

TABLE 373 MEA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, UNIT (2014–2018)

TABLE 374 MEA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, UNIT (2019–2024)

TABLE 375 MEA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2014–2018)

TABLE 376 MEA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 377 MEA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2018)

TABLE 378 MEA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)

TABLE 379 MEA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2018)

TABLE 380 MEA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)

TABLE 381 MEA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2014–2018)

TABLE 382 MEA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)

TABLE 383 MEA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2014–2018)

TABLE 384 MEA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)

TABLE 385 MEA EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2018)

TABLE 386 MEA EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)

TABLE 387 MEA EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2014–2018)

TABLE 388 MEA EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2019–2024)

TABLE 389 SAUDI ARABIA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2018)

TABLE 390 SAUDI ARABIA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)

TABLE 391 SAUDI ARABIA EMBOLIC AGENTS MARKET, BY TYPE, $M (2014–2018)

TABLE 392 SAUDI ARABIA EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)

TABLE 393 SAUDI ARABIA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2014–2018)

TABLE 394 SAUDI ARABIA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 395 SAUDI ARABIA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2018)

TABLE 396 SAUDI ARABIA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)

TABLE 397 SAUDI ARABIA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2018)

TABLE 398 SAUDI ARABIA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)

TABLE 399 SAUDI ARABIA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2014–2018)

TABLE 400 SAUDI ARABIA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)

TABLE 401 SAUDI ARABIA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2014–2018)

TABLE 402 SAUDI ARABIA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)

TABLE 403 SAUDI ARABIA EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2018)

TABLE 404 SAUDI ARABIA EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)

TABLE 405 SOUTH AFRICA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2018)

TABLE 406 SOUTH AFRICA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)

TABLE 407 SOUTH AFRICA EMBOLIC AGENTS MARKET, BY TYPE, $M (2014–2018)

TABLE 408 SOUTH AFRICA EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)

TABLE 409 SOUTH AFRICA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2014–2018)

TABLE 410 SOUTH AFRICA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)

TABLE 411 SOUTH AFRICA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2018)

TABLE 412 SOUTH AFRICA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)

TABLE 413 SOUTH AFRICA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2018)

TABLE 414 SOUTH AFRICA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)

TABLE 415 SOUTH AFRICA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2014–2018)

TABLE 416 SOUTH AFRICA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)

TABLE 417 SOUTH AFRICA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2014–2018)

TABLE 418 SOUTH AFRICA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)

TABLE 419 SOUTH AFRICA EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2018)

TABLE 420 SOUTH AFRICA EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)

TABLE 421 LIST OF OTHER PLAYERS AND THEIR OFFERINGS

TABLE 422 STRYKER CORPORATION – AT A GLANCE

TABLE 423 STRYKER CORPORATION – KEY FINANCIAL SUMMARY

TABLE 424 SIRTEX MEDICAL LIMITED – AT A GLANCE

TABLE 425 SIRTEX MEDICAL LIMITED – KEY FINANCIAL SUMMARY

TABLE 426 MERIT MEDICAL SYSTEMS INC. – AT A GLANCE

TABLE 427 MERIT MEDICAL SYSTEMS INC. – KEY FINANCIAL SUMMARY

TABLE 428 MERIL LIFE SCIENCES PVT. LTD. – AT A GLANCE

TABLE 429 ACANDIS GMBH – AT A GLANCE

TABLE 430 TERUMO CORPORATION – AT A GLANCE

TABLE 431 TERUMO CORPORATION – KEY FINANCIAL SUMMARY

TABLE 432 MEDTRONIC PLC – AT A GLANCE

TABLE 433 MEDTRONIC PLC – KEY FINANCIAL SUMMARY

TABLE 434 KANEKA CORPORATION – AT A GLANCE

TABLE 435 KANEKA CORPORATION – KEY FINANCIAL SUMMARY

TABLE 436 JOHNSON & JOHNSON – AT A GLANCE

TABLE 437 JOHNSON & JOHNSON – KEY FINANCIAL SUMMARY

TABLE 438 BOSTON SCIENTIFIC CORPORATION – AT A GLANCE

TABLE 439 BOSTON SCIENTIFIC CORPORATION – KEY FINANCIAL SUMMARY

TABLE 440 ABBOTT LABORATORIES – AT A GLANCE

TABLE 441 ABBOTT LABORATORIES – KEY FINANCIAL SUMMARY

TABLE 442 GUERBET – AT A GLANCE

TABLE 443 GUERBET – KEY FINANCIAL SUMMARY

TABLE 444 BALT EXTRUSION SAS – AT A GLANCE

 

LIST OF FIGURES

 

FIG 1 RESEARCH SCOPE

FIG 2 RESEARCH METHODOLOGY

FIG 3 REGIONAL SPLIT OF PRIMARY OF PRIMARY AND SECONDARY RESEARCH

FIG 4 DATA TRIANGULATION APPROACH

FIG 5 GLOBAL EMBOLOTHERAPY MARKET SUMMARY

FIG 6 PERCENTAGE INCREASE IN HEALTHCARE EXPENDITURE, BY COUNTRY

FIG 7 BARGAINING POWER OF BUYERS

FIG 8 BARGAINING POWER OF SUPPLIERS

FIG 9 INTENSITY OF RIVALRY

FIG 10 THREAT OF NEW ENTRANTS

FIG 11 THREAT OF SUBSTITUTES

FIG 12 SNAPSHOT OF GLOBAL EMBOLOTHERAPY MARKET

FIG 13 GLOBAL EMBOLOTHERAPY MARKET, BY PRODUCT, UNIT (2014–2024)

FIG 14 GLOBAL EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2024)

FIG 15 GLOBAL EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2024)

FIG 16 GLOBAL EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2024)

FIG 17 GLOBAL EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2024)

FIG 18 WORLDWIDE MAJOR MARKETS FOR EMBOLOTHERAPY

FIG 19 NORTH AMERICA EMBOLOTHERAPY MARKET SNAPSHOT

FIG 20 NORTH AMERICA EMBOLOTHERAPY MARKET, BY PRODUCT, UNIT (2014–2024)

FIG 21 NORTH AMERICA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2024)

FIG 22 NORTH AMERICA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2024)

FIG 23 NORTH AMERICA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2024)

FIG 24 NORTH AMERICA EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2024)

FIG 25 NORTH AMERICA EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2014–2024)

FIG 26 EUROPE EMBOLOTHERAPY MARKET SNAPSHOT

FIG 27 EUROPE EMBOLOTHERAPY MARKET, BY PRODUCT, UNIT (2014–2024)

FIG 28 EUROPE EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2024)

FIG 29 EUROPE EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2024)

FIG 30 EUROPE EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2024)

FIG 31 EUROPE EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2024)

FIG 32 EUROPE EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2014–2024)

FIG 33 APAC EMBOLOTHERAPY MARKET SNAPSHOT

FIG 34 APAC EMBOLOTHERAPY MARKET, BY PRODUCT, UNIT (2014–2024)

FIG 35 APAC EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2024)

FIG 36 APAC EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2024)

FIG 37 APAC EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2024)

FIG 38 APAC EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2024)

FIG 39 APAC EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2014–2024)

FIG 40 LATAM EMBOLOTHERAPY MARKET SNAPSHOT

FIG 41 LATAM EMBOLOTHERAPY MARKET, BY PRODUCT, UNIT (2014–2024)

FIG 42 LATAM EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2024)

FIG 43 LATAM EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2024)

FIG 44 LATAM EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2024)

FIG 45 LATAM EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2024)

FIG 46 LATAM EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2014–2024)

FIG 47 MEA EMBOLOTHERAPY MARKET SNAPSHOT

FIG 48 MEA EMBOLOTHERAPY MARKET, BY PRODUCT, UNIT (2014–2024)

FIG 49 MEA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2014–2024)

FIG 50 MEA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2014–2024)

FIG 51 MEA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2014–2024)

FIG 52 MEA EMBOLOTHERAPY MARKET, BY END USER, $M (2014–2024)

FIG 53 MEA EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2014–2024)

FIG 54 STRYKER CORPORATION – REVENUE SPLIT BY BUSINESS SEGMENT AND GEOGRAPHY (2018)

FIG 55 SIRTEX MEDICAL LIMITED – REVENUE SPLIT BY GEOGRAPHY (2018)

FIG 56 MERIT MEDICAL SYSTEMS INC. – REVENUE SPLIT BY BUSINESS SEGMENT AND GEOGRAPHY (2018)

FIG 57 TERUMO CORPORATION – REVENUE SPLIT BY BUSINESS SEGMENT AND GEOGRAPHY (2018)

FIG 58 MEDTRONIC PLC – REVENUE SPLIT BY BUSINESS SEGMENT AND GEOGRAPHY (2018)

FIG 59 JOHNSON & JOHNSON – REVENUE SPLIT BY BUSINESS SEGMENT AND GEOGRAPHY (2018)

FIG 60 BOSTON SCIENTIFIC CORPORATION – REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2018)

FIG 61 ABBOTT LABORATORIES – REVENUE SPLIT BY BUSINESS AREA AND GEOGRAPHY (2018)

FIG 62 GUERBET – REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2018)

Place An Order
USD 4900 USD 5900 USD 7500
Customized Report Solution

Get a bespoke market intelligence solution

 
We are committed to ensuring the highest level of client satisfaction
Quality Acknowledgement
Quality Acknowledgement

Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you

Unmatched Standards
Unmatched Standards

Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights

Reach Us
Reach Us Whenever You Need Us

With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required

Data Security
Complete Data Security

We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws